Zero to hero: the peculiar case of Orphacol
This article was originally published in Scrip
Executive Summary
Orphacol has come full circle. It has just been announced that the orphan drug – for the treatment of inborn errors in primary bile synthesis, a rare and potentially fatal condition affecting about 100 people in Europe – has just earned the highest ASMR rating for clinical benefit from the notoriously stringent French health authorities.